Literature DB >> 6516445

Cytochrome P-450-dependent oxidation of felodipine--a 1,4-dihydropyridine--to the corresponding pyridine.

C Bäärnhielm, I Skånberg, K O Borg.   

Abstract

Felodipine, a 1,4-dihydropyridine diester, is metabolized to its corresponding pyridine analogue by rat-liver microsomes. Kinetic studies showed similar Km, Vmax and t1/2 for the formation of the pyridine metabolite and the disappearance of felodipine, indicating that oxidation of felodipine to the corresponding pyridine analogue is the major pathway of metabolism. Response to inhibitors such as CO, SKF 525-A and metyrapone indicates participation of cytochrome P-450 in the aromatization of felodipine. Phenobarbital pretreatment markedly increased the metabolism of felodipine and its pyridine analogue. Felodipine pretreatment had no effect on the cytochrome P-450 concn. in rat-liver microsomes, nor on the rate of its own metabolism, but a slight increase was observed in the rate of metabolism of four standard substrates.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6516445     DOI: 10.3109/00498258409151470

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  12 in total

1.  A population study of the pharmacokinetics of felodipine.

Authors:  E Blychert; B Edgar; D Elmfeldt; T Hedner
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

2.  Factors affecting the pharmacokinetics of nifedipine.

Authors:  A G Renwick; J Le Vie; V F Challenor; D G Waller; B Gruchy; C F George
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

3.  The trans-hepatic extraction of nifedipine.

Authors:  V F Challenor; D G Waller; A G Renwick; B S Gruchy; C F George
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

Review 4.  Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  E Saltiel; A G Ellrodt; J P Monk; M S Langley
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

Review 5.  Felodipine clinical pharmacokinetics.

Authors:  P H Dunselman; B Edgar
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

6.  Stereoselective pharmacokinetics of oral felodipine and nitrendipine in healthy subjects: correlation with nifedipine pharmacokinetics.

Authors:  P A Soons; T M Mulders; E Uchida; H C Schoemaker; A F Cohen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  Metabolism of [14C] felodipine, a new vasodilating drug, in healthy volunteers.

Authors:  K J Hoffmann; L Andersson
Journal:  Drugs       Date:  1987       Impact factor: 9.546

8.  Pharmacokinetics of felodipine in patients with liver disease.

Authors:  C G Regårdh; B Edgar; R Olsson; M Kendall; P Collste; C Shansky
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

9.  Felodipine reduces the absorption of theophylline in man.

Authors:  T Bratel; B Billing; R Dahlqvist
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

10.  The pharmacokinetics of oral nifedipine--a population study.

Authors:  A G Renwick; D R Robertson; B Macklin; V Challenor; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.